IFNA1 and renal cell carcinoma: In patients with renal cell carcinoma (RCC), sorafenib can significantly improve progression-free survival (PFS) from 2.8 to 5.6 months compared to that of placebo [8] and sunitinib can increase PFS from 5.0 to 11.0 months compared to that of interferon (IFN) [9].